NCT06674941View on ClinicalTrials.gov

A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 24, 2023

Primary Completion Date

November 14, 2023

Study Completion Date

November 14, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

Teprotumumab

Administered as an SC injection.

Trial Locations (1)

89113-2237

PPD Development, LP, Las Vegas

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT06674941 - A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants | Biotech Hunter | Biotech Hunter